Efavirenz in the therapy of HIV infection

Bibliography

• UNAIDS. AIDS epidemic update: December 2007. Available from: http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf. [Accessed 11 June, 2009]
   Google Scholar
• Scaling up access to antiretroviral therapy to low- and midlde-income countries: global and regional progress in 2008 WHO, UNAIDS, UNICEF. Availabe from: http://wwwwhoint/hiv/mediacentre/ias_2009pdf. [Accessed 31 August, 2009]
   Google Scholar
• Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008. p. 1-128. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. [Accessed 27, March 2008]
   Google Scholar
• Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach RW, 2006. Available from: http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf. [Accessed 27 March, 2008]
   Google Scholar
• UNAIDS. AIDS epidemic update : December 2007. Available from http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf. [Accessed 1 April, 2008.2007]
   Google Scholar
• Gulick RM, Ribaudo HJ, Shikuma CM, Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006;296(7):769-81
   PubMed Web of Science ®Google Scholar
• Gallant JE, Staszewski S, Pozniak AL, Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004;292(2):191-201
   PubMed Web of Science ®Google Scholar
• Staszewski S, Morales-Ramirez J, Tashima KT, Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999;341(25):1865-73
   PubMed Web of Science ®Google Scholar
• Squires K, Lazzarin A, Gatell JM, Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004;36(5):1011-9
   PubMed Web of Science ®Google Scholar
• Riddler SA, Haubrich R, DiRienzo AG, Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008;358(20):2095-106
   PubMed Web of Science ®Google Scholar
• Hirsch MS, Gunthard HF, Schapiro JM, Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008;47(2):266-85
   PubMed Web of Science ®Google Scholar
• van Leth F, Phanuphak P, Ruxrungtham K, Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004;363(9417):1253-63
   PubMed Web of Science ®Google Scholar
• Haubrich RH, Riddler SA, DiRienzo AG, Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009;23(9):1109-18
   PubMed Web of Science ®Google Scholar
• Nunez M, Soriano V, Martin-Carbonero L, SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals. HIV Clin Trials 2002;3(3):186-94
   PubMedGoogle Scholar
• Ghosn J, Chaix ML, Delaugerre C. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors. AIDS Rev 2009;11(3):165-73
   PubMed Web of Science ®Google Scholar
• Scherrer AU, Hasse B, von Wyl V, Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS). HIV Med 2009;10(10):647-56
   Google Scholar
• FDA - Approval Letter. Available from: http://www.fda.gov/cder/foi/appletter/1998/20972ltr.pdf. [Accessed 12 July 2009]
   Google Scholar
• Sustiva® Prescribing Information. Bristol-Myers Squibb Company. March 2009
   Google Scholar
• ChemIDplus Advanced. Available from: http://chem.sis.nlm.nih.gov/chemidplus/chemidheavy.jsp. Accessed July 12 2009
   Google Scholar
• FDA Antiretrovirals Approved and Tentatively Approved in Association with the President's Emergency Plan Expedited Review Process. FDA, U.S. Department of Health and Human Services. Available from: http://www.fda.gov/InternationalPrograms/FDABeyondOurBordersForeignOffices/AsiaandAfrica/ucm119231.htm. [Accessed 12 August 2009]
   Google Scholar
• von Hentig N, Koenigs C, Elanjikal S, Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines. Eur J Med Res 2006;11(9):377-80
   PubMed Web of Science ®Google Scholar
• Ren Y, Nuttall JJ, Egbers C, High prevalence of subtherapeutic plasma concentrations of efavirenz in children. J Acquir Immune Defic Syndr 2007;45(2):133-6
   PubMed Web of Science ®Google Scholar
• Wintergerst U, Hoffmann F, Jansson A, Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children. J Antimicrob Chemother 2008;61(6):1336-9
   Google Scholar
• Saitoh A, Fletcher CV, Brundage R, Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism. J Acquir Immune Defic Syndr 2007;45(3):280-5
   PubMed Web of Science ®Google Scholar
• Fletcher CV, Brundage RC, Fenton T, Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial. Clin Pharmacol Ther 2008;83(2):300-6
   PubMed Web of Science ®Google Scholar
• Schneider S, Peltier A, Gras A, Efavirenz in human breast milk, mothers', and newborns' plasma. J Acquir Immune Defic Syndr 2008;48(4):450-4
   PubMed Web of Science ®Google Scholar
• Teglas JP, Quartier P, Treluyer JM, Tolerance of efavirenz in children. AIDS 2001;15(2):241-3
   PubMed Web of Science ®Google Scholar
• Starr SE, Fletcher CV, Spector SA, Efavirenz liquid formulation in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002;21(7):659-63
   PubMed Web of Science ®Google Scholar
• ter Heine R, Scherpbier H, Crommentuyn K, Population phramacokinetics in children. Current pediatric dosing guidelines may result in sub-therapeutic concentrations. Annual meeting of Amercian Society of Clinical Pharmaclogy and Therapeutics (ASCPT) Orlando, FL, 2008
   Google Scholar
• Hirt D, Urien S, Olivier M, Is the recommended dose of efavirenz optimal in young West African HIV-infected children? (ANRS 12103). Antimicrob Agents Chemother 2009;53(10):4407-13
   Google Scholar
• Mutlib AE, Chen H, Nemeth GA, Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. Drug Metab Dispos 1999;27(11):1319-33
   PubMed Web of Science ®Google Scholar
• Desta Z, Saussele T, Ward B, Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 2007;8(6):547-58
   PubMed Web of Science ®Google Scholar
• Ward BA, Gorski JC, Jones DR, The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003;306(1):287-300
   PubMed Web of Science ®Google Scholar
• Bumpus NN, Kent UM, Hollenberg PF. Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms. J Pharmacol Exp Ther 2006;318(1):345-51
   PubMed Web of Science ®Google Scholar
• di Iulio J, Fayet A, Arab-Alameddine M, In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics2009;19(4):300-9
   PubMed Web of Science ®Google Scholar
• Blank A, Hellstern V, Schuster D, Efavirenz treatment and false-positive results in benzodiazepine screening tests. Clin Infect Dis 2009;48(12):1787-9
   PubMed Web of Science ®Google Scholar
• Lang T, Klein K, Richter T, Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J Pharmacol Exp Ther 2004;311(1):34-43
   PubMed Web of Science ®Google Scholar
• Rotger M, Colombo S, Furrer H, Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005;15(1):1-5
   PubMedGoogle Scholar
• Tsuchiya K, Gatanaga H, Tachikawa N, Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 2004;319(4):1322-6
   PubMed Web of Science ®Google Scholar
• Klein K, Lang T, Saussele T, Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 2005;15(12):861-73
   PubMed Web of Science ®Google Scholar
• Haas DW, Ribaudo HJ, Kim RB, Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group Study. AIDS 2004;18(18):2391-400
   PubMed Web of Science ®Google Scholar
• Rodriguez-Novoa S, Barreiro P, Rendon A, Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis 2005;40(9):1358-61
   PubMed Web of Science ®Google Scholar
• Ribaudo HJ, Haas DW, Tierney C, Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2006;42(3):401-7
   PubMed Web of Science ®Google Scholar
• Wyen C, Hendra H, Vogel M, Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother 2008;61(4):914-18
   PubMed Web of Science ®Google Scholar
• Rotger M, Tegude H, Colombo S, Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 2007;81(4):557-66
   PubMed Web of Science ®Google Scholar
• Kwara A, Lartey M, Sagoe KW, CYP2B6 (c.516G–>T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br J Clin Pharmacol 2009;67(4):427-36
   PubMed Web of Science ®Google Scholar
• Gatanaga H, Hayashida T, Tsuchiya K, Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis 2007;45(9):1230-7
   PubMed Web of Science ®Google Scholar
• Cabrera SE, Santos D, Valverde MP, Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. Antimicrob Agents Chemother 2009;53(7):2791-8
   PubMed Web of Science ®Google Scholar
• Arab-Alameddine M, Di Iulio J, Buclin T, Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther 2009;85(5):485-94
   PubMed Web of Science ®Google Scholar
• Wang J, Sonnerborg A, Rane A, Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics 2006;16(3):191-8
   PubMed Web of Science ®Google Scholar
• Nyakutira C, Roshammar D, Chigutsa E, High prevalence of the CYP2B6 516G–>T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 2008;64(4):357-65
   PubMed Web of Science ®Google Scholar
• Haas DW, Smeaton LM, Shafer RW, Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult AIDS Clinical Trials Group Study. J Infect Dis 2005;192(11):1931-42
   PubMed Web of Science ®Google Scholar
• Gross R, Aplenc R, Tenhave T, Slow efavirenz metabolism genotype is common in Botswana. J Acquir Immune Defic Syndr 2008;49(3):336-7
   PubMed Web of Science ®Google Scholar
• Leger P, Dillingham R, Beauharnais CA, CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti. J Infect Dis 2009;200(6):955-64
   PubMed Web of Science ®Google Scholar
• Mehlotra RK, Ziats MN, Bockarie MJ, Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur J Clin Pharmacol 2006;62(4):267-75
   PubMed Web of Science ®Google Scholar
• Puthanakit T, Tanpaiboon P, Aurpibul L, Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children. Antivir Ther 2009;14(3):315-20
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Updated November 3, 2008. Available from: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. [Accessed 12 August 2009]
   Google Scholar
• Poirier JM, Guiard-Schmid JB, Meynard JL, Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitors. AIDS 2006;20(7):1087-9
   PubMed Web of Science ®Google Scholar
• Sekar VJ, De Pauw M, Marien K, Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers. Antivir Ther 2007;12(4):509-14
   PubMed Web of Science ®Google Scholar
• Hsu A, Isaacson J, Brun S, Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003;47(1):350-9
   PubMed Web of Science ®Google Scholar
• Sustiva® Prescribing Information. Bristol-Myers Squibb Company. September 2009
   Google Scholar
• Matteelli A, Regazzi M, Villani P, Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients. Curr HIV Res 2007;5(3):349-53
   PubMed Web of Science ®Google Scholar
• Weiner M, Benator D, Peloquin CA, Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis. Clin Infect Dis 2005;41(9):1343-9
   PubMed Web of Science ®Google Scholar
• Damle B, LaBadie R, Crownover P, Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers. Br J Clin Pharmacol 2008;65(4):523-30
   PubMed Web of Science ®Google Scholar
• Clarke SM, Mulcahy FM, Tjia J, The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol 2001;51(3):213-7
   PubMed Web of Science ®Google Scholar
• Robertson SM, Penzak SR, Lane J, A potentially significant interaction between efavirenz and phenytoin: a case report and review of the literature. Clin Infect Dis 2005;41(2):e15-18
   PubMed Web of Science ®Google Scholar
• El-Ibiary SY, Cocohoba JM. Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives. Eur J Contracept Reprod Health Care 2008;13(2):123-32
   PubMed Web of Science ®Google Scholar
• Novak RM, Chen L, MacArthur RD, Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 2005;40(3):468-74
   PubMed Web of Science ®Google Scholar
• Cassetti I, Madruga JV, Etze A, The safety and efficacy of tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) in antiretroviral-naïve patients through seven years. 17th International AIDS Conference, Mexico City, Mexico; August 3-8, 2008. Abstract TUPE0057
   Google Scholar
• Robbins GK, De Gruttola V, Shafer RW, Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003;349(24):2293-303
   PubMed Web of Science ®Google Scholar
• Gulick RM, Ribaudo HJ, Shikuma CM, Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004;350(18):1850-61
   PubMed Web of Science ®Google Scholar
• Gallant JE, Rodriguez AE, Weinberg WG, Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005;192(11):1921-30
   PubMed Web of Science ®Google Scholar
• Saag M HJ, Goodrich J, Reanalysis of the MERIT study with the enhanced TrofileTM assay. In: Abstracts of the Forty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC, USA; 2008. Abstract H-1232
   Google Scholar
• Markowitz M, Nguyen BY, Gotuzzo E, Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007;46(2):125-33
   PubMed Web of Science ®Google Scholar
• Markowitz M NB-Y, Gotuzzo E, Sustained antiretroviral efficacy of raltegravir as part of combination ART in treatment-naI¨ve HIV-1-infected patients: 96-week data. In: Abstracts of the Seventeenth International AIDS Conference, Mexico City, Mexico, 2008. Abstract TUAB0102
   Google Scholar
• Marzolini C, Telenti A, Decosterd LA, Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001;15(1):71-5
   PubMed Web of Science ®Google Scholar
• Saitoh A, Hull AD, Franklin P, Myelomeningocele in an infant with intrauterine exposure to efavirenz. J Perinatol 2005;25(8):555-6
   PubMedGoogle Scholar
• Watts DH. Teratogenicity risk of antiretroviral therapy in pregnancy. Curr HIV/AIDS Rep 2007;4(3):135-40
   PubMedGoogle Scholar
• Department of Health and Human Services. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Updated February 23, 2009. Available from: http://aidsinfo.nih.gov/contentfiles/PediatricGuidelines.pdf. [Accessed June 27 2009]
   Google Scholar
• van Leth F, Phanuphak P, Stroes E, Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004;1(1):e19
   PubMed Web of Science ®Google Scholar
• McComsey G, Bhumbra N, Ma JF, Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. Pediatrics 2003;111(3):e275-81
   PubMed Web of Science ®Google Scholar
• Scherpbier HJ, Bekker V, Pajkrt D, Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen. Pediatrics 2007;119(3):e705-15
   PubMed Web of Science ®Google Scholar
• Rathore M, McKinney R, Hu C, PACTG protocol 1021: a phase I/II study of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents. Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA; 2008. Abstract 581
   Google Scholar